Pharmacotherapy of anxious disorders

Human Psychopharmacology

Volumn 17, Issue 8, 2002, Pages 383-400

  Bourine, Michel ^a,b   Lambert, Olivier ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antidepressants; Benzodiazepines; GAD; OCD; Panic disorder; PTSD; Selective serotonin reuptake inhibitors; Social anxiety

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; FLUMAZENIL; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; HISTAMINE H1 RECEPTOR AGONIST; HYDRAZINE DERIVATIVE; IMIPRAMINE; LAMOTRIGINE; LOFEPRAMINE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PIMOZIDE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIMELDINE;

AGITATION; AMNESIA; ANXIETY DISORDER; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DROWSINESS; DRUG ABUSE; DRUG ALCOHOL INTERACTION; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EJACULATION DISORDER; GENERALIZED ANXIETY DISORDER; HUMAN; META ANALYSIS; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; ORGASM DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOCIAL PHOBIA; SWEATING; TRANQUILIZING ACTIVITY; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PHOBIC DISORDERS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 0036904318     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.435     Document Type: Review

References (260)

1. Ackerman DL, Greeland S. 2002. Multivariate meta-analysis of controlled drug studies for obsessive compulsive disorder. J Clin Psychopharmacol 22: 309-317.
2. Allgulander C, Cloniger CR, Przybeck TR, et al. 1998. Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacol Bull 34: 165-166.
3. American Psychiatric Association. 1998. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 155(Suppl. 5): 1-34.
4. Andrade L, Eaton WW, Wilcoat HD. 1996. Lifetime co-morbidity of panic attacks and major depression in population-based study: age of onset. Psychol Med 26: 991-996.
5. Bakish D, Hooper CL, Filtreau MJ, et al. 1996. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 32: 135-141.
6. Bakish D, Saxena XM, Bowen R, et al. 1993. Reversible monoamine oxidase - a inhibitors in panic disorder. Clin Neuropharmacol 16(Suppl. 2): S77-S82.
7. Baldwin D. 2000. Clinical experience with paroxetine in social anxiety disorder. Int Clin Psychopharmacol 15(Suppl. 1): 19-24.
8. Baldwin D, Bobes J, Stein DJ, et al. 1999. Paroxetine in social phobia/social anxiety disorder: randomized, double-blind, placebo-controlled study. Br J Psychiatry 175: 120-126.
9. Ballenger JC. 1992. Medication discontinuation in panic disorder. J Clin Psychiatry 53(Suppl. 3): 26-31.
10. Ballenger JC. 1999. Current treatment of the anxiety disorder in adults. Biol Psychiatry 46: 1579-1594.
11. Ballenger JC, Davidson RT, Lecrubier Y, et al. 1998a. Consensus statement on panic disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 59(Suppl. 8): 47-54.
12. Ballenger JC, Wheadon DE, Steiner M, et al. 1998b. Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155: 36-42.
13. Battaglia M, Bernardeschi L, Politi E, et al. 1995. Comorbidity of panic and somatization disorder: a genetic-epidemiological approach. Compr Psychiatry 36: 411-420.
14. Beidel DC, Turner SM. 1997. At risk for anxiety: psychopathology in the offspring of anxious parents. J Am Acad Child Adolesc Psychiatry 36: 918-924.
15. Berlant JL. 2001. Topiramate in post-traumatic stress disorder. J Clin Psychiatry 62(Suppl. 17): 60-63.
16. Berlant J, Van K. 2002. Open-label topiramate as primary or adjunctive therapy in chronic civilian post-traumatic stress disorder: a primary report. J Clin Psychiatry 63: 15-20.
17. Bisserbe JC, Lane R, Flament MF, et al. 1997. Double-blind comparison of sertraline and Faraone SV, Challoff clomipramine in patients with obsessive-compulsive disorder. Eur Psychiatry 12: 82-93.
18. Bisserbe JC, Weiller E, Boyer P, et al. 1996. Social phobia in primary care: level of recognition and drug use. Int J Psychopharmacol 11(Suppl. 3): 25-28.
19. Black DW, Wesner R, Bowers W, et al. 1993. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50: 44-50.
20. Blazer DG, Hughes D, George LK, et al. 1991. Generalized anxiety disorder. In Psychiatric Disorders in America: The Epidemiologic Catchment Area Study, Robins LN, Regnier DA (eds). The Free Press: New York; 180-203.
21. Bourin M, Hascoet M. 2001. Drug mechanisms in anxiety. Curr Op Invest Drug 2: 259-265.
22. Boyer W. 1995. Serotonin uptake inhibitors are superior to alprazolam and imipramine in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10: 45-49.
23. Brady K, Pearlstein T, Asnis GM, et al. 2000. Efficacy and safety of sertraline treatment of post-traumatic stress disorder: a randomized controlled trial. JAMA 283: 563-564.
24. Bremner JD, Randall P, Scott TM, et al. 1995. MRI-based measurement of hippocampal volume in patients with combat-related post-traumatic stress disorder. Am J Psychiatry 152: 973-981.
25. Breslau N. 2001a. Outcomes of post-traumatic stress disorder. J Clin Psychiatry 62(Suppl. 17): 55-59.
26. Breslau N. 2001b. The epidemiology of post-traumatic stress disorder: what is the extent of the problem? J Clin Psychiatry 62(Suppl. 17): 16-22.
27. Breslau N, Davis GC, Andreski P, et al. 1991. Traumatic events and post-traumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry 48: 216-222.
28. Brunello N, Davidson JRT, Deahl M, et al. 2001. Post-traumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 43:150-162.
29. Cameron OG, Smith CB, Lee MA, et al. 1990. Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 28: 3-20.
30. Carter RM, Wittchen HU, Pfister H, et al. 2001. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety 3: 78-88.
31. Charney DS, Deutch AY, Krystal JH, et al. 1993. Psychobiologic mechanism of post-traumatic stress disorder. Arch Gen Psychiatry 50: 249-306.
32. Chouinard G. 1992. Sertraline in the treatment of obsessive-compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 7(Suppl. 2): 37-41.
33. Chouinard G, Greist J, Jenike M, et al. 1990. Results of a double-blind placebo-controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 26: 279-284.
34. Clineschmidt BV, Zacchei AG, Totaro JA, et al. 1978. Fenfluramine and brain serotonin. Ann NY Acad Sci 305: 22-241.
35. Clomipramine Collaborative Study Group. 1991. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48: 730-738.
36. Connor KM, Sutherland SM, Tupler LA, et al. 1999. Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. Br J Psychiatry 175: 17-22.
37. Coupland NJ, Bell C, Potokar JP, et al. 2000. Flumazenil challenge in social phobia. Depress Anxiety 11: 27-30.
38. Cowleys DS, Roy-Byrne PP, Hommer DW, et al. 1991. Benzodiazepine sensitivity in anxiety disorders (Abstract). Biol Psychiatry 29(Suppl. 29): 57A.
39. Cross-National Collaborative Panic Study. 1992. Second phase investigator. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo. Br J Psychiatry 160: 191-202.
40. Curtis GC, Massana J, Udina C, et al. 1993. Maintenance therapy of panic disorder. J Psychiatr Res 27(Suppl. 1): 127-142.
41. Da Sylva B, Fontaine R, Gammans D, et al. 1992. Efficacy of nefazodone in patients suffering from major depressive disorder and panic disorder. Biol Psychiatry 31: 169A.
42. Dansky BS, Roitz JC, Brady KT. 1997. Post-traumatic stress disorder and substance abuse: use of research in a clinical setting. J Trauma Stress 10: 141-148.
43. Davidson JRT. 1998. Long-term treatment of panic disorder. J Clin Psychiatry 59(Suppl. 8): 17-21.
44. Davidson JRT, Connor KM. 1999. Management of post-traumatic syndrome disorder diagnosis and therapeutic issues. J Clin Psychiatry 60(Suppl. 18): 33-38.
45. Davidson JRT, Dupont RC, Hedges D, et al. 1999. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60: 528-535.
46. Davidson JR, Hughes DC, George LK, et al. 1994. The boundary of social phobia: exploring the threshold. Arch Gen Psychiatry 51: 975-983.
47. Davidson JRT, Kudler H, Smith R, et al. 1990. Treatment of post-traumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 47: 259-266.
48. Davidson JRT, Kudler HS, Sauders WB, et al. 1993a. Predicting response to amitriptyline in post-traumatic stress disorder. Am J Psychiatry 150: 1024-1029.
49. Davidson JRT, Malik ML, Sutherland SN. 1997. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol 12: 291-296.
50. Davidson J, Pearlstein T, Londborg P, et al. 2001a. Efficacy of sertraline in preventing relapse of post-traumatic stress disorder: result of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 158: 1974-1981.
51. Davidson JR, Potts N, Richichi E, et al. 1993b. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13: 423-428.
52. Davidson JRT, Rothbaum BO, van der Kolk BA, et al. 2001b. Multicenter, double-blind comparison of sertraline and placebo in the treatment of post-traumatic stress disorder. Arch Gen Psychiatry 58: 485-492.
53. Davidson JRT, Walker JI, Kilts C. 1987. A pilot study of phenelzine in post-traumatic stress disorder. Br J Psychiatry 150: 252-255.
54. Davidson JRT, Weisler RH, Malik ML. 1998. Fluvoxamine in civilians with post-traumatic stress disorder. J Clin Psychopharmacol 18: 93-95.
55. De Martinis NA, Schneizer E, Rickels K. 1996. An open label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 57: 245-248.
56. Deakin JFW, Graeff FG. 1991. Critique: 5HT and mechanisms of defense. J Psychopharmacol 5: 305-315.
57. Den Boer JA, Westemberg HG. 1990. Serotonin function in panic disorder: a double blind placebo-controlled study with fluvoxamine. Psychopharmacology 102: 85-94.
58. Dolberg OT, Iancu I, Sansson Y, et al. 1996. The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 19: 129-147.
59. Duffy JD, Malloy PF. 1994. Efficacy of buspirone in the treatment of post-traumatic stress disorder: an open trial. Ann Clin Psychiatry 6: 33-37.
60. Eaton W, Dryman A, Weissman M. 1991. Panic and phobia. In Psychiatric Disorder in America: The Epidemiologic Catchment Area Study, Robins L, Regier D (eds). Free Press: New York; 53-80.
61. Ellingrod VL. 1998. Pharmacotherapy of primary obsessive-compulsive disorder: review of literature. Pharmacotherapy 18: 936-960.
62. Escalona R, Tupler LA, Saur CD, et al. 1997. Screening for trauma history on an inpatient affective-disorder unit: a pilot study. J Trauma Stress 10: 299-305.
63. Federoff IC, Taylor S. 2001. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 21: 311-324.
64. Feighner JP, Cohn JB. 1989. Analysis of individual symptoms in generalized anxiety: a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 21: 124-130.
65. Ferrarese C, Appolonio I, Frigo M, et al. 1990. Decreased density of benzodiazepine receptors in anxiety disorders in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 82: 169-173.
66. Fesler FA. 1991. Valproate in combat-related post-traumatic stress disorder. J Clin Psychiatry 52: 361-364.
67. Fichtner CG, Crayton JW. 1994. Buspirone in combat-related post-traumatic stress disorder. J Clin Psychiatry 57: 66-72.
68. Flament MF, Bisserbe JC. 1997. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 58(Suppl. 12): 18-22.
69. Francobanderia G. 2001. Olanzapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 46: 356-358.
70. Freeman CPL, Trimble MR, Deakin JFW, et al. 1994. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55: 301-305.
71. Fyer AJ, Liebowitz MR, Gorman JM, et al. 1998. Effects of clonidine on alprazolam discontinuation in panic patients: a pilot study. J Clin Psychopharmacol 8: 270-274.
72. Fyer AJ, Mannuzza S, Chapman TF, et al. 1996. Panic disorder and social phobia: effects of comorbidity on familial transmission. Anxiety 2: 173-178.
73. Gammans RE, Stringfellow JC, Hvizdos AJ, et al. 1992. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomized, controlled studies. Neuropsychobiology 25: 193-201.
74. Gelenberg AJ, Lyliard RB, Rudolph RL. 2000. Efficacy of venlafaxine ER capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283: 3082-3088.
75. Gerdes T, Yates WR, Clancy G. 1995. Increasing identification and referral of panic disorder over the past decade. Psychosomatics 36: 480-486.
76. Gerlentner CS, Uhde TW, Cimbolic O, et al. 1991. Cognitive behavioral and pharmalogical treatments of social phobia: a placebo-controlled study. Arch Gen Psychiatry 48: 938-945.
77. Goodman WK. 1999. Obsessive compulsive disorder diagnosis and treatment. J Clin Psychiatry 60(Suppl. 18): 27-32.
78. Goodman WK, Kozak MJ, Liebowitz M, et al. 1996. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicenter, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 11: 21-29.
79. Goodman WK, McDougle CJ, Barr LC, et al. 1993. Biological approaches to treatment resistant obsessive-compulsive disorder. J Clin Psychiatry 54(Suppl. 6): 16-26.
80. Goodman WK, McDougle CJ, Price LH, et al. 1990. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive-compulsive disorder? J Clin Psychiatry 51: 36-43.
81. Gorman JM, Liebowitz MR, Fryer AJ. 1987. A open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7: 329-332.
82. Grady TA, Pigott TA, L'Heureux F, et al. 1993. Double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 150: 819-821.
83. Greist J, Chouinard G, Duboff E, et al. 1995a. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52: 289-295.
84. Greist JH, Jefferson JW, Koback KA, et al. 1995b. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 52: 53-60.
85. Greist JH, Jefferson JW, Kobak KA. 1995c. A 1 year double-blind placebo-contolled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 57-65.
86. Gurwitch RH, Sullivan MA, Long PJ. 1998. The impact of trauma and disaster on young children. Child Adolesc Psychiatr Clin N Am 7: 19-32.
87. Hamner MB, Brodick PS, Labbate LA. 2001. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 13: 141-146.
88. Hansen ES, Hasselbach S, Law I, et al. 2002. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. Int J Neuropsychopharmacol 5: 1-10.
89. Hertzberg MA, Feldman ME, Beckham JC, et al. 1998. Open trial of nefazodone for combat-related post-traumatic stress disorder. J Clin Psychiatry 59: 460-464.
90. Hertzberg MA, Feldman ME, Beckham JC, et al. 1996. Trial of trazodone for post-traumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol 16: 294-298.
91. Hidalgo RB, Davidson JR. 2000. Selective serotonin reuptake inhibitors in post-traumatic stress disorder. J Psychopharmacol 14: 70-76.
92. Hidalgo RB, Davidson JR. 2001. Generalized anxiety disorder: an important clinical concern. Med Clin N Am 85: 691-710.
93. Hoehn-Saric R, McLeod DR, Hipsley PA. 1993. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 13: 321-326.
94. Hoehn-Saric R, McLeod DR, Zimmerli WD. 1988. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 49: 293-301.
95. Hogben BL, Cornfield RB. 1981. Treatment of traumatic war neurosis with phenelzine. Arch Gen Psychiatry 38: 440-445.
96. Hollander E, Kwon JH, Stein DJ, et al. 1996. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 57(Suppl. 8): 3-6.
97. Huguelet P, McQuillan A. 1996. Neuroimaging and neurobiology of obsessive-compulsive disorder. Encephale 22: 41-45.
98. Iny LJ, Pecnold J, Suranyi Cadotte BE, et al. 1994. Studies of a neurochemical link between depression, anxiety, and stress from H3 imipramine and H3 paroxetine binding on human platelets. Biol Psychiatry 36: 281-291.
99. Jenike MA, Baer L, Greist JH. 1990. Clomipramine vs fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacity. J Clin Psychopharmacol 10: 122-124.
100. Jenike MA, Baer L, Minichiello WE, et al. 1997. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 154: 1261-1264.
101. Joseph S, Yule W, Williams R, et al. 1993. Increased substance use in survivors of the Herald of Free Enterprise disaster. Br J Med Psychol 66: 185-191.
102. Judd FK, Chua P, Lynch C, et al. 1991. Fenfluramine augmentation of clomipramine treatment of obsessive-compulsive disorder. Aust NZ J Psychiatry 25: 412-414.
103. Judd LL, Kessler RC, Paulus MP, et al. 1998. Comorbidity as a fundamental feature of generalized anxiety disorder: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand 98(Suppl. 393): 6-11.
104. Kan CC, Bretelet MH, Zitman FG. 1997. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand 96: 85-93.
105. Karno M, Golding JM, Sorenson SB, et al. 1988. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094-1099.
106. Kasper S, Resinger E. 2001. Panic disorder: the place of benzodiazepine and selective reuptake inhibitors. Eur Neuropsychopharmacol 11: 307-321.
107. Katz IR, Reynolds CF, Alexopoulos GS, et al. 2002. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: polled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 50: 18-25.
108. Katzelnik DJ, Kobak KA, Greist JH. 1995. Sertraline for social phobia: a double blind, placebo-controlled crossover study. Am J Psychiatry 152: 1368-1371.
109. Kessler RC, McGonagle K, Zhao S, et al. 1998. Social phobia subtype in the national comorbidity survey. Am J Psychiatry 155: 613-619.
110. Kessler RC, Sonnega A, Bromet E, et al. 1995. Post-traumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 52: 1048-1060.
111. Kline NA, Dow BM, Brown SA, et al. 1993. Sertraline efficacy in depressed combat veterans with post-traumatic stress disorder. J Clin Psychopharmacol 13: 107-113.
112. Koran L, McElroy SL, Davidson JRT. 1996. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16: 121-129.
113. Koran LM, Hackett E, Rubin A, et al. 2002. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159: 88-95.
114. Koran LM, Thienemann ML, Davenport R. 1996. Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 153: 783-788.
115. Kosten TR, Frank JB, Dan E, et al. 1991. Pharmacotherapy for post-traumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 179: 366-370.
116. Koster TR, Mason JW, Giller EL, et al. 1987. Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. Psychoneuroendocrinology 12: 13-20.
117. Kronig MH, Apter J, Bystrisky A, et al. 1999. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19: 172-176.
118. Krutson B, Wolkowitz OM, Cole SW, et al. 1998. Selective alteration of personality and social behavior by serotoninergic intervention. Am J Psychiatry 155: 373-379.
119. La Porta LD, Ware MR. 1992. Buspirone and the treatment of post-traumatic stress disorder. J Clin Psychopharmacol 12: 133-134.
120. Lecrubier Y. 1998. Comorbidity in social anxiety disorder: impact on disease burden and management. J Clin Psychiatry 59(Suppl. 17): 33-37.
121. Lecrubier Y. 1998. Impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 59(Suppl. 8): 11-14.
122. Lecrubier Y, Bakker A, Dunbar G, et al. 1997. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 95: 145-152.
123. Leinonen E, Lepola U, Koponen H, et al. 2000. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci 25: 25-32.
124. Leonard HL, Swedo SE, Lenane MC, et al. 1993. A 2 to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 50: 429-439.
125. Leonard HL. 1997. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl. 14): 39-45.
126. Lepola U, Wade A, Leinonen E, et al. 1998. A controlled, prospective, 1 year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59: 528-534.
127. Liebowitz MR. 1987. Social phobia. Mod Probl Pharmacopsychiatry 22: 141-173.
128. Liebowitz MR, Schneier F, Campeas R, et al. 1992. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 53: 159-168.
129. Liebowitz MR, Stein MB, Tancer M, et al. 2002. A randomized, double blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63: 66-74.
130. Lindesay J. 1991. Phobic disorders in the elderly. Br J Psychiatry 159: 531-541.
131. Lipper S, Davidson JRT, Grady TA, et al. 1986. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 72: 849-854.
132. Lopez-Ibor JJ, Saiz J, Cottraux J, et al. 1996. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Eur Neuropsychopharmacol 6: 111-118.
133. Lott M, Greist JH, Jefferson JW, et al. 1997. Brofaramine for social phobia: a multicentre, placebo-controlled, double blind study. J Clin Psychopharmacol 17: 255-260.
134. Lydiard RB. 1996. Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Anxiety 2: 61-70.
135. Magee WJ, Eaton WW, Wittchen HU, et al. 1996. Agoraphobia, simple phobia and social phobia in the national comorbidity survey. Arch Gen Psychiatry 53: 159-168.
136. Malison RT, McDougle CJ, van Dyck CH, et al. 1995. Beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's syndrome. Am J Psychiatry 152: 1359-1361.
137. Mancini C, Van Ameringen M. 1996. Paroxetine in social phobia. J Clin Psychiatry 57: 519-522.
138. Markowitz JS, Weissman MH, Oulette R, et al. 1989. Quality of life in panic disorder. Arch Gen Psychiatry 46: 984-992.
139. Marshall JR. 1996. Comorbidity and its effect on panic disorder. Bull Menninger Clin 60(Suppl. 2): 39-53.
140. Marshall RD, Beebe KL, Oldham M, et al. 2001. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 158: 1982-1988.
141. Marshall RD, Schneier FR, Fallon BA, et al. 1998. An open trial of paroxetine in patients with noncombat-related, chronic post-traumatic stress disorder. J Clin Psychopharmacol 18: 10-18.
142. Martenyi F, Brown EB, Zhang H, et al. 2002. Fluoxetine versus placebo in post-traumatic stress disorder. J Clin Psychiatry 63: 199-206.
143. Mattes J. 1986. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1: 170-173.
144. McDougle CJ, Epperson CN, Pelton GH, et al. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57: 794-801.
145. McDougle CJ, Goodman WK, Leckman JF, et al. 1993. Limited therapeutic effect of addition of buspirone in fluoxamine refractory obsessive-compulsive disorder. Am J Psychiatry 150: 647-649.
146. McDougle CJ, Goodman WK, Leckman JF, et al. 1994. Haloperidol addition in fluvoxamine refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with or without tics. Arch Gen Psychiatry 51: 302-308.
147. McDougle CJ, Goodman WK, Price LH, et al. 1990. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 147: 652-654.
148. McDougle CJ, Price LH, Goodman WK, et al. 1991. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 11: 175-184.
149. McFarlane AC, Atchison M, Rafalowicz E, et al. 1994. Physical symptoms in post-traumatic stress disorder. J Psychosom Res 38: 715-726.
150. Melik ME. 1978. Life changes and illness: illness behavior of male in the recovery period of a natural disaster. J Health Soc Behav 19: 335-342.
151. Michelson D, Lyliard RB, Tamura R, et al. 1998. The Fluoxetine Panic Disorder Study Group. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 155: 1570-1577.
152. Modigh K, Westemberg HG, Erikson E. 1992. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 12: 251-261.
153. Moller HJ, Volz HP, Reimann JW, et al. 2001. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59-65.
154. Montgomery SA, Kasper S, Stein DJ, et al. 2001. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 16: 75-86.
155. Montgomery SA, McIntyre A, Osterheider M, et al. 1993. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III obsessive-compulsive disorder: the Lilly European OCD Study Group. Eur Neuropsychopharmacol 3: 143-152.
156. Müller N. 2000. Frühstadien der Sozialen Phobie: Risiken, Erscheinungsformen und Konsequenzen. Dissertation. University of Bamberg.
157. Nagy LM, Morgan CA, Southwick SM, et al. 1993. Open prospective trial of fluoxetine for post-traumatic stress disorder. J Clin Psychopharmacol 13: 107-113.
158. Nair N, Bakish D, Saxena B, et al. 1996. Comparison of fluvoxamine, imipramine and placebo in the treatment of outpatients with panic disorder. Anxiety 2: 192-198.
159. Norman TR, Ellen SR, Burrows GD. 1997. Benzodiazepines in anxiety disorders: managing therapeutics and dependence. Med J Aust 167: 490-495.
160. Noyes R, Jr. 2001. Comorbidity in generalized anxiety disorder. Psychiatr Clin N Am 24: 41-55.
161. Noyes R. 1985. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin N Am 8: 119-132.
162. Noyes JR, Moroz G, Davidson JR, et al. 1997. Moclobenine in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 17: 247-254.
163. Nutt DJ, Bell CJ, Malizia AC. 1998. Brain mechanisms of social anxiety disorder. J Clin Psychiatry 59(Suppl. 17): 4-11.
164. Oehrberg S, Christiansen PE, Behnke K, et al. 1995. Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 167: 374-379.
165. Otto MW, Pollack MH, Maki M et al. 2001. Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparison with patients with panic disorder. Depress Anxiety 14: 209-213.
166. Otto MW, Tuby KS, Gould RA. 2001. An effect-size analysis of the relative efficacy and tolerability of serotonin reuptake inhibitors for panic disorder. Am J Psychiatry 158: 1989-1992.
167. Pecknold JC. 1993. Discontinuation reactions to alprazolam in panic disorder. J Psychiatr Res 27(Suppl. 1): 155-170.
168. Pecknold JC, Luthe L, Iny L, et al. 1995. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatr Neuorosci 20: 193-198.
169. Pelissolo A, Bisserbe JC. 1994. Dependence on benzodiazepine: clinical and biological aspects. Encephale 20: 147-157.
170. Pigot TA, Pato MY, Bernstein SE, et al. 1990. Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Arch Gen Psychiatry 47: 926-932.
171. Pigott TA, L'heureux F, Hill JL, et al. 1992. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 11-18.
172. Pigott TA, Pato M, L'heurex F, et al. 1991. A controlled comparison of adjuvent lithium carbamate or thyroïd hormone in clomipramine-treated patient with obsessive-compulsive disorder. J Clin Psychopharmacol 11: 242-248.
173. Pohl RB, Wolkow RM, Clary CM. 1998. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155: 1189-1195.
174. Pollack MH. 1999. Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry 60(Suppl. 9): 20-26.
175. Pollack MH, Otto MW, Worthington JJ, et al. 1998. Sertraline in the treatment of panic disorder. Arch Gen Psychiatry 55: 1010-1016.
176. Pollack MH, Worthington JJ, Otto MW, et al. 1996. Venlafaxine for panic disorder: result from a double blind, placebo-controlled study. Psychopharmacol Bull 32: 667-670.
177. Pollack MH, Zaninelli R, Goddard A, et al. 2001. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62: 350-357.
178. Rasmussen SA. 1987. Lithium and tryptophan augmentation in clomipramine resistant obsessive-compulsive disorder. Am J Psychiatry 141: 1283-1285.
179. Rasmussen SA, Eisen JL. 1994. Epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 55(Suppl. 10): 5-14.
180. Rasmussen SA, Eisen JL. 1997. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 58(Suppl. 13): 9-13.
181. Rauch SL, van der Kolk BA, Fisler RE, et al. 1996. A symptom provocation study of post-traumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 53: 380-387.
182. Resnick HS, Kilpatrick DG, Danski BS, et al. 1993. Prevalence of civilian trauma and post-traumatic stress disorder in a representational national sample of women. J Consult Clin Psychol 61: 984-991.
183. Rickels K, Case WG, Downing RW, et al. 1983. Long-term diazepam therapy and clinical outcome. JAMA 250: 767-771.
184. Rickels K, Downing R, Schweizer E, et al. 1993a. Antidepressant for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 50: 884-895.
185. Rickels K, Pollack MH, Sheehan DV, et al. 2000. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157: 968-974.
186. Rickels K, Schweizer E, Weiss S, et al. 1993b. Maintenance drug treatment for panic disorder, II: short and long-term outcome after drug taper. Arch Gen Psychiatry 50: 61-68.
187. Risse SC, Whitters A, Burke J, et al. 1990. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced post-traumatic stress disorder. J Clin Psychiatry 51: 206-209.
188. Rocca P, Ferrero P, Gualerzi A, et al. 1991. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr Scand 84: 537-544.
189. Rocca P, Fonzo V, Scotta M, et al. 1907. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95: 444-450.
190. Rogers MP, Warshaw MG, Goisman RM, et al. 1999. Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders. Depress Anxiety 10: 1-7.
191. Rosembaum JP, et al. (the clonazepam panic disorder dose-reponse study group). 1997. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-reponse study of efficacy, safety and discontinuance. J Clin Psychopharmacol 17: 390-400.
192. Rosembaum JP, Biederman J, Bolduc Murphy EA, et al. 1993. Behavioral inhibition in childhood: a risk factor for anxiety disorders. Harv Rev Psychiatry 1: 2-16.
193. Roth LM. 1986. Substance use and mental health among Vietnam veterans. In The Vietnam Veteran Redefined, Boulanger G, Kadushin C (eds). Lawrence Erlbaum: Hillsdale, NJ; 61-78.
194. Sandmann J, Lorch B, Bandelow B, et al. 1998. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 31: 117-121.
195. Sasson Y, Zohar J, Chopra M, et al. 1997. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 58(Suppl. 12): 7-10.
196. Saxena S, Brody AL, Maidment KM, et al. 1999. Localized orbito-frontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21: 683-693.
197. Scheeringa MS, Peebles CD, Zeanah CH. 2001. Toward establishing procedural, criterion, and discriminant validity for PTSD in early childhood. J Acad Child Adolesc Psychiatry 40: 52-60.
198. Scheeringa MS, Zeanah CH, Larrieu JA. 1995. Two approaches of the diagnosis of post-traumatic stress disorder in infancy and early chilhood. J Acad Child Adolesc Psychiatry 34: 191-200.
199. Schneier FR, Goetz D, Campeas R, et al. 1998. Placebo-controlled trial of moclobenine in social phobia. Br J Psychiatry 172: 70-77.
200. Schneier FR, Johnson J, Hornig CD, et al. 1992. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 49: 282-288.
201. Schweizer E, Patterson W, Rickels K, et al. 1993a. Double-blind, placebo-controlled study of once-a-day, sustained-release preparation for alprazolam in the treatment of panic disorder. Am J Psychiatry 150: 1210-1215.
202. Schweizer E, Rickels K, Weiss S. 1993b. Maintenance drug treatment of panic disorder, I. Result of a prospective, placebo-controlled, comparison of alprazolam and imipramine. Arch Gen Psychiatry 50: 51-60.
203. Sevy S, Papadimitriou GN, Surmont DW, et al. 1989. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 25: 141-152.
204. Shader RJ, Greenblatt DJ. 1993. Use of benzodiazepine in anxiety disorder. N Engl J Med 328: 1398-1405.
205. Shalev AY, Freedman S, Peri T, et al. 1998. Prospective study of post-traumatic stress disorder and depression following trauma. Am J Psychiatry 15: 630-637.
206. Sheehan DV. 1999. Current concepts in treatment. J Clin Psychiatry 60(Suppl. 18): 16-21.
207. Sheehan DV, Ballenger JC, Jacobson G. 1980. Treatment of endogenous anxiety with phobia, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 37: 51-59.
208. Sheikh JL, Londborg P, Clary CM, et al. 2000. The efficacy of sertraline in panic disorder: combined results from two fixed dose studies. Int Clin Psychopharmacol 15: 335-342.
209. Simpson HB, Schneier FR, Campeus R, et al. 1998. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 18: 132-135.
210. Singer HS, Hahn IH, Moran TH. 1991. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 30: 558-562.
211. Smeraldi E, Erzegovesi S, Bianchi I, et al. 1992. Fluvoxamine vs clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psychiatry 8: 63-65.
212. Solomon SD, Davidson JRT. 1997. Trauma: prevalence, impairment, service use, and cost. J Clin Psychiatry 58(Suppl.): 5-11.
213. Southwick SM, Krystal JH, Bremner JD, et al. 1997. Noradrenergic and serotoninergic function in post-traumatic stress disorder. Arch Gen Psychiatry 54: 749-758.
214. Sramek JJ, Hong WW, Hamids S, et al. 1999. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety 9: 131-134.
215. Stein DJ. 2001. Comorbidity in generalized anxiety disorder: impact and implication. J Clin Psychiatry 62(Suppl. 11): 29-34.
216. Stein DJ, Berk M, Els C, et al. 1999. A double-blind placebo-controlled trial of paroxetine in management of social phobia (social anxiety disorder) in South Africa. SA Med J 89: 402-406.
217. Stein DJ, Seedat S, van der Linden GJ, et al. 2000. Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15(Suppl. 2): S31-S39.
218. Stein DJ, Spadaccini E, Hollander E. 1995. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 11-18.
219. Stein MB, Chartier MJ, Hazen RN, et al. 1996. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 16: 218-222.
220. Stein MB, Chavira DA. 1998a. Subtypes of social phobia and comorbidity depression and other anxiety disorders. J Affect Disord 50(Suppl. 1): 511-516.
221. Stein MB, Forde DR, Anderson G, et al. 1997. Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Am J Psychiatry 154: 1120-1126.
222. Stein MB, Koverola C, Hanna C, et al. 1998b. Hippocampal volume in women victimized by childhood sexual abuse. Psychol Med 27: 951-959.
223. Stein MB, Liebowitz MR, Lydiard RB, et al. 1998c. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled-trial. JAMA 280: 708-713.
224. Stemberger RT, Turner SM, Beidel DC, et al. 1995. Social phobia: an analysis of possible developmental factors. J Abnorm Psychol 104: 526-531.
225. Tancer ME, Mailman RB, Stein RB, et al. 1994/95. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1: 216-223.
226. Taylor LH. 1997. Fluoxetine efficacy in social phobia. J Clin Psychiatry 58: 124-125.
227. Tesar GE, Rosenbaum JF, Pollack MH, et al. 1991. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 52: 69-76.
228. Tiihonen J, Kuikka J, Bergstrom K, et al. 1987. Dopamine reuptake site density in patient with social phobia. Mod Probl Pharmacopsychiatry 22: 141-173.
229. Tollefson GD, Rampey AH, Potvin JH, et al. 1994. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51: 559-567.
230. Tork I, Hornung JP. 1990. Raphe nucleï and serotoninergic system. In The Human Nervous System, Paxinos G (ed.). Academic Press: San Diego; 1001-1022.
231. Tuckel R, Polat A, Ozdemir O. 2002. Comorbid conditions in obsessive-compulsive disorder. Compr Psychiatry 43: 204-209.
232. Tucker P, Zaninelli R, Yehuda R, et al. 2001. Paroxetine in the treatment of chronic post-traumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62: 860-868.
233. Van der Kolk BA, Dryfuss D, Michaels M, et al. 1994. Fluoxetine in post-traumatic stress disorder. J Clin Psychiatry 55: 517-522.
234. Van der Linden GJ, Stein DJ, van Balkom AJ. 2000. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15(Suppl. 2): S15-S23.
235. Van Vliet IM, Den Boer JA, Westemberg HG. 1994. Psychopharmacological treatment of social phobia: a double blind placebo-controlled study with fluoxamine. Psychopharmacology 115: 128-134.
236. Van Vliet IM, den Boer JA, Westemberg HGM. 1996. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 16: 299-306.
237. Versiani M, Nardi AE, Mundim FD, et al. 1992. Pharmacotherapy of social phobia: a controlled study with moclobenine and phenelzine. Br J Psychiatry 161: 353-360.
238. Wade AG, Lepola U, Koponen HJ, et al. 1997. The effect of citalopram in panic disorder. Br J Psychiatry 170: 549-553.
239. Wagstaff AJ, Cheer SM, Matheson AJ, et al. 2002a. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 62: 655-703.
240. Wagstaff AJ, Cheer SM, Matheson AJ, et al. 2002b. Spotlight on paroxetine in psychiatric disorder in adults. CNS Drug 16: 425-434.
241. Weissman NM. 1991. Panic disorder: impact on quality of life. J Clin Psychiatry 52(Suppl. 2): 6-9.
242. Weissman MM, Bland RC, Canino GJ, et al. 1997. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 54: 305-309.
243. Weissman MM, Bland RC, Canino GJ, et al. 1994. The cross-national epidemiology of obsessive-compulsive disorder. J Clin Psychiatry 55(Suppl. 3): 5-10.
244. Weizman R, Tanne Z, Granek M, et al. 1987. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 138: 289-292.
245. Westemberg HMG. 1998. The nature of social anxiety disorder. J Clin Psychiatry 59(Suppl. 17): 20-24.
246. Wittchen HU. 2000. The many faces of social anxiety disorder. Int Clin Psychopharmacol 15(Suppl. 1): 7-12.
247. Wittchen HU, Hoyer J. 2001. Generalized anxiety disorder: nature and course. J Clin Psychiatry 62(Suppl. 11): 15-19.
248. Wittchen HU, Nelson CB, Kessler RC. 1999. Social fears and DSM-IV social phobia in a community sample of adolescents and young adults: prevalence, risk factor and comorbidity. Psychol Med 29: 309-329.
249. Wittchen HU, Zhao S, Kessler RC, et al. 1994. DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychiatry 51: 355-364.
250. Wolf B, Griffiths RR. 1991. Physical dependence on benzodiazepines: difference within the class. Drug Alcohol Dep 29: 153-156.
251. Woodman CL, Noyes R. 1994. Panic disorder: treatment with valproate. J Clin Psychiatry 55: 134-136.
252. Yehuda R. 2001. Biology of post-traumatic stress disorder. J Clin Psychiatry 62(Suppl. 17): 41-46.
253. Yehuda R, McFarlane AC. 1995. Conflict between current knowledge about post-traumatic stress disorder and its original conceptual basis. Am J Psychiatry 152: 1705-1713.
254. Yonkers KA, Warshaw MG, Massion, AO, et al. 1996. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 168: 308-313.
255. Yonkers KA, Zlotnick C, Allworth J, et al. 1998. Is the course of panic disorder the same in women and men? Am J Psychiatry 155: 596-602.
256. Zatrick DF, Marmar CR, Weiss DS, et al. 1999. Post-traumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatry 156: 804-805.
257. Zitterl W, Meszaros K, Twaroch T, et al. 1999. Efficacy of fluoxetine, in Austrian patients with obsessive-compulsive disorder. Wien Klin Wochenschr 111: 439-442.
258. Zohar J, Amital D, Miodownik C, et al. 2002. Double-blind placebo-controlled pilot study of sertraline in military veterans with post-traumatic stress disorder. J Clin Psychopharmacol 22: 190-195.
259. Zohar J, Judge R. 1996. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 169: 468-474.
260. Zohar J, Westemberg HG. 2000. Anxiety disorder: a review of tricyclic antidepressants and selective reuptake inhibitors. Acta Psychiatr Scand 403: 39-49.